The Life Scientific
Bahija Jallal on the biotech revolution in cancer therapies
Sep 5, 2023
Bahija Jallal, CEO of Immunocore, shares her journey in developing biopharmaceutical cancer treatments, focusing on targeted therapies. She discusses the potential of new biotech therapies, advancements in T cell tracking, and the revolutionizing impact of Immunocore's treatment for metastatic uvial melanoma. She reflects on her personal background, the challenges faced by women in the industry, and the importance of diversity of thought in leadership. She serves as a role model for women in science and emphasizes the need for inspiration and humility.
28:17
Episode guests
AI Summary
AI Chapters
Episode notes
Podcast summary created with Snipd AI
Quick takeaways
- Personal resilience and unwavering pursuit of knowledge are crucial in shaping a successful career in the biotech industry.
- Targeted cancer therapies, such as T cell receptor therapy, have the potential to transform cancer into a manageable, chronic disease.
Deep dives
Enhancing T Cells for Targeted Attacks on Harmful Cells
The podcast explores the potential of bio-pharmaceuticals to improve the function of T cells in detecting and eliminating cancerous and infected cells. By modifying the sensors on T cells to make them more potent and visible, scientists can enhance their ability to track and destroy harmful cells. This approach differs greatly from traditional chemotherapy, which has a broader impact on both cancerous and healthy cells. The use of targeted therapies that mimic the power of the immune system shows promising results in prolonging the lives of cancer patients.
Remember Everything You Learn from Podcasts
Save insights instantly, chat with episodes, and build lasting knowledge - all powered by AI.
